Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nanobiotix ADR Representing Ord Shs NBTX

Healthcare Biotechnology
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and... see more

Recent & Breaking News (NDAQ:NBTX)

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

GlobeNewswire 13 days ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Voting Rights and Shares Capital of the Company

GlobeNewswire August 8, 2024

Voting Rights and Shares Capital of the Company

GlobeNewswire July 9, 2024

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

GlobeNewswire June 12, 2024

Voting Rights and Shares Capital of the Company

GlobeNewswire June 11, 2024

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

GlobeNewswire June 2, 2024

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

GlobeNewswire May 28, 2024

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 23, 2024

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

GlobeNewswire May 22, 2024

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

GlobeNewswire May 21, 2024

Voting Rights and Shares Capital of the Company

GlobeNewswire May 16, 2024

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

GlobeNewswire May 15, 2024

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

GlobeNewswire May 14, 2024

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

GlobeNewswire April 24, 2024

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

GlobeNewswire April 17, 2024

Voting Rights and Shares Capital of the Company

GlobeNewswire April 10, 2024

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

GlobeNewswire April 2, 2024

Nanobiotix to Present at Upcoming Investor Conferences in March

GlobeNewswire March 6, 2024

Voting Rights and Shares Capital of the Company

GlobeNewswire February 13, 2024